-- Radiopharm Theranostics is focused on development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs
-- Highly prospective portfolio of four distinct & clearly differentiated platform technologies
-- Pipeline candidate selection based on their potential to be First to Market or Best in Class in the respective therapeutic applications
-- Deep clinical pipeline of five Phase 2 trials and two Phase 1 trials ongoing, with a total of 133 patients dosed to date
-- Key executives secured including former AAA/Novartis CCO Riccardo Canevari as CEO & MD, Prof David Mozley as CMO and Dr Thom Tulip as CTO
-- Radiopharm raised A$50m as part of the IPO, listing with a market capitalisation of A$152m
-- The IPO received strong support from a range of institutional, sophisticated and retail investors both locally and overseas
-- Bell Potter and Baker Young were Joint Lead Managers to the IPO
-- Watch a pre-listing investor presentation by Executive Chairman Paul Hopper and Managing Director & CEO Riccardo Canevari
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, commences trading on the Australian Securities Exchange (ASX) today after completing a strongly supported initial public offering (IPO) that raised A$50m from investors.
The IPO saw Radiopharm issue 83.3 million new shares at A$0.60 per share, giving the company a market capitalisation of A$152m at the issue price.
For more information, download the attached PDF.
Download this document
